http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102399777-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_279b4c171d4ef5996ccd96c093a55ddf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate | 2011-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d9c3db8a624401dc4945001fa59a06f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8014e0b6093b0e3d8f6654cc0afd34d2 |
| publicationDate | 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102399777-B |
| titleOfInvention | Recombinant plasmid and recombinant oncolytic virus prepared by using the same |
| abstract | The invention discloses a recombinant plasmid and a recombinant oncolytic virus prepared by using the same. In the invention, a recombinant oncolytic virus vector is obtained by inserting a DNA (Deoxyribonucleic Acid) fragment A (including the following two elements from upstream to downstream: a U6 promoter element and 1504-siRN encoding element) and a DNA fragment B (a TERTp promoter element, an E1A gene element and an E1B55K-E1B19K gene element) into an oncolytic virus vector. A culturing supernatant containing the recombinant oncolytic virus can be obtained by carrying out cell transfection on the recombinant oncolytic virus vector and culturing the recombinant oncolytic virus vector. In the recombinant oncolytic virus, the expression of adenovirus early replicator E1A is started by a tumor specific promoter (TERTp promoter) so that expression is not available or the expression value is extremely low in the normal cell and 1504-siRN is simultaneously expressed in the tumor cell. The recombinant adenovirus has the advantages of very good tumor cell specificity, capability of giving play to oncolytic and antitumor double effects and very high medical values. |
| priorityDate | 2011-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.